BRAF and melanoma: While the interaction between GM and targeted therapies in melanoma is underexplored, early evidence suggests that BRAF inhibitors may promote immune activation by reducing immunosuppressive molecules and cytokines within the TME and enhancing CD8 + T-cell cytotoxicity13,14.